Citalopram versus other antidepressants for depression
by ncbi.nlm.nih.gov
Major depression is a severe mental illness characterised by a persistent and unreactive low mood and loss of all interest and pleasure, usually accompanied by a range of symptoms including appetite change, sleep disturbance, fatigue, loss of energy, poor concentration, psychomotor symptoms, inappropriate guilt and morbid thoughts of death. Antidepressant drugs remain the mainstay of treatment in moderate?to?severe major depression. During the last 20 years, selective serotonin reuptake inhibitors (SSRIs) have progressively become the most commonly prescribed antidepressants. Citalopram, one of the first SSRIs introduced in the market, is the racemic mixture of S? and R?enantiomer. In the present review we assessed the evidence for the efficacy, acceptability and tolerability of citalopram in comparison with all other antidepressants in the acute?phase treatment of major depression. Thirty?seven randomised controlled trials (more than 6000 participants) were included in the present review. In terms of efficacy, citalopram was more efficacious than other reference compounds like paroxetine or reboxetine, but worse than escitalopram. In terms of side effects, citalopram was more acceptable than older antidepressants, like tricyclics. Based on these findings, we conclude that clinicians should focus on practical or clinically relevant considerations including differences in efficacy and side?effect profiles.
Abstract
Background: Recent US and UK clinical practice guidelines recommend that second?generation antidepressants should be considered amongst the best first?line options when drug therapy is indicated for a depressive episode. Systematic reviews have already highlighted some differences in efficacy between second?generation antidepressants. Citalopram, one of the first selective serotonin reuptake inhibitors (SSRI) introduced in the market, is one of these antidepressant drugs that clinicians use for routine depression care.
Objectives: To assess the evidence for the efficacy, acceptability and tolerability of citalopram in comparison with tricyclics, heterocyclics, other SSRIs and other conventional and non?conventional antidepressants in the acute?phase treatment of major depression.
Search methods: We searched The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register and the Cochrane Central Register of Controlled Trials up to February 2012. No language restriction was applied. We contacted pharmaceutical companies and experts in this field for supplemental data.
Selection criteria: Randomised controlled trials allocating patients with major depression to citalopram versus any other antidepressants.
Data collection and analysis: Two reviewers independently extracted data. Information extracted included study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy (the number of patients who responded or remitted), patient acceptability (the number of patients who failed to complete the study) and tolerability (side?effects).
Main results: Thirty?seven trials compared citalopram with other antidepressants (such as tricyclics, heterocyclics, SSRIs and other antidepressants, either conventional ones, such as mirtazapine, venlafaxine and reboxetine, or non?conventional, like hypericum). Citalopram was shown to be significantly less effective than escitalopram in achieving acute response (odds ratio (OR) 1.47, 95% confidence interval (CI) 1.08 to 2.02), but more effective than paroxetine (OR 0.65, 95% CI 0.44 to 0.96) and reboxetine (OR 0.63, 95% CI 0.43 to 0.91). Significantly fewer patients allocated to citalopram withdrew from trials due to adverse events compared with patients allocated to tricyclics (OR 0.54, 95% CI 0.38 to 0.78) and fewer patients allocated to citalopram reported at least one side effect than reboxetine or venlafaxine (OR 0.64, 95% CI 0.42 to 0.97 and OR 0.46, 95% CI 0.24 to 0.88, respectively).
Authors' conclusions: Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy, tolerability and acceptability. Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics, reboxetine and venlafaxine, however, it seemed to be less efficacious than escitalopram. As with most systematic reviews in psychopharmacology, the potential for overestimation of treatment effect due to sponsorship bias and publication bias should be borne in mind when interpreting review findings. Economic analyses were not reported in the included studies, however, cost effectiveness information is needed in the field of antidepressant trials.
Source: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0047318/
Tuesday, May 12, 2026
Clonidine Treatment Decisions: Dosing, Uses, and What Patients Should Know
Clonidine is an antihypertensive medication with a unique central nervous system mechanism that sets it apart from the more commonly prescribed first-line blood pressure drugs. Understanding why clonidine is prescribed, how dosing decisions are made, and what monitoring looks like helps patients work effectively with their care team when this medication is part of their treatment plan. Clonidine works by stimulating alpha-2 adrenergic receptors in the brainstem, specifically in the nucleus of the solitary tract and the locus coeruleus. Activating these receptors reduces sympathetic outflow from the central nervous system, which lowers heart rate and decreases arterial tone. This results in blood pressure reduction without the direct peripheral vasodilation or sodium-water balance effects of other antihypertensive classes. Because of this central mechanism, clonidine is particularly useful in certain clinical scenarios. Patients who experience poorly controlled blood pressure despite multiple standard antihypertensive medications sometimes respond well to clonidine as an add-on agent. Patients with hypertension complicated by autonomic instability, certain types of pain, or ADHD in pediatric populations may also benefit from clonidine for multiple reasons simultaneously. Oral clonidine doses for hypertension typically start at 0.1 mg twice daily. Doses are adjusted gradually based on blood pressure response and tolerability, usually in 0.1 mg increments at weekly intervals. Most patients remain in the 0.2 to 0.6 mg daily range. Doses above 2.4 mg daily carry higher sedation and adverse effect risk. A transdermal clonidine patch provides an alternative delivery system for patients who prefer less frequent dosing or have compliance challenges with multiple daily oral tablets. The patch is replaced weekly and delivers consistent medication levels throughout the application period. Skin reactions at the patch site occur in some patients and may limit this route for certain individuals. Abrupt discontinuation of clonidine requires special attention. Stopping clonidine suddenly, particularly at higher doses, can trigger rebound hypertension, where blood pressure rises rapidly and significantly above pretreatment levels. This rebound effect results from the sudden restoration of sympathetic activity that clonidine had been suppressing. Any reduction or stop of clonidine therapy should be done gradually under medical supervision. Sedation and dry mouth are the most commonly reported side effects. Clonidine's central sedating effects overlap with its blood pressure mechanism, meaning drowsiness is a pharmacological consequence at therapeutic doses, particularly when treatment is first initiated or doses are increased. For patients discussing their hypertension treatment with a provider, reviewing information about clonidine treatment decisions helps clarify what makes this medication appropriate for specific situations and what patients should expect from therapy. For broader context on blood pressure medications, how different drug classes compare, and what monitoring involves, exploring blood pressure medication options and treatment guidance supports well-informed clinical conversations.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.